Biological Activity
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
In Vitro
AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [125I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GROα-induced Ca2+ flux in human neutrophils loaded with fluo-3 dye[1].
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Target
125I-IL-8-CXCR2
References & source
[1]. Norman P. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.










